JP2010540570A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540570A5
JP2010540570A5 JP2010527303A JP2010527303A JP2010540570A5 JP 2010540570 A5 JP2010540570 A5 JP 2010540570A5 JP 2010527303 A JP2010527303 A JP 2010527303A JP 2010527303 A JP2010527303 A JP 2010527303A JP 2010540570 A5 JP2010540570 A5 JP 2010540570A5
Authority
JP
Japan
Prior art keywords
composition
antigen
composition according
amphiphilic compound
hydrophobic carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010527303A
Other languages
English (en)
Japanese (ja)
Other versions
JP5591705B2 (ja
JP2010540570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/001747 external-priority patent/WO2009043165A1/en
Publication of JP2010540570A publication Critical patent/JP2010540570A/ja
Publication of JP2010540570A5 publication Critical patent/JP2010540570A5/ja
Application granted granted Critical
Publication of JP5591705B2 publication Critical patent/JP5591705B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010527303A 2007-10-03 2008-10-02 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用 Expired - Fee Related JP5591705B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97719707P 2007-10-03 2007-10-03
US60/977,197 2007-10-03
PCT/CA2008/001747 WO2009043165A1 (en) 2007-10-03 2008-10-02 Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof

Publications (3)

Publication Number Publication Date
JP2010540570A JP2010540570A (ja) 2010-12-24
JP2010540570A5 true JP2010540570A5 (enExample) 2011-11-10
JP5591705B2 JP5591705B2 (ja) 2014-09-17

Family

ID=40525804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527303A Expired - Fee Related JP5591705B2 (ja) 2007-10-03 2008-10-02 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用

Country Status (7)

Country Link
EP (1) EP2195022A4 (enExample)
JP (1) JP5591705B2 (enExample)
CN (1) CN101815529B (enExample)
AU (1) AU2008307042B2 (enExample)
BR (1) BRPI0817484B1 (enExample)
CA (1) CA2700828C (enExample)
WO (1) WO2009043165A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
IN2014CN02581A (enExample) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
WO2014153636A1 (en) 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
CN105044328A (zh) * 2015-05-28 2015-11-11 首都医科大学附属北京佑安医院 Elispot预包被培养板及其制备方法
US11160861B2 (en) 2015-11-18 2021-11-02 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
CN109328070A (zh) * 2016-05-04 2019-02-12 免疫疫苗技术有限公司 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法
JP7125197B2 (ja) 2016-09-27 2022-08-24 イミューノヴァクシーン テクノロジーズ インコーポレイテッド ヒト対象において抗体免疫応答を誘導するために低投与体積b細胞エピトープ組成物を使用する方法
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ, インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
EP3768242A4 (en) * 2018-03-20 2021-12-08 ImmunoVaccine Technologies Inc. METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES
US20250127887A1 (en) * 2021-02-16 2025-04-24 Barinthus Biotherapeutics North America, Inc. Self-Assembling Nanoparticles Based On Amphiphilic Peptides
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI944052A0 (fi) * 1992-03-03 1994-09-02 Daiichi Seiyaku Co Oraalinen rokote
US5736141A (en) * 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
US6110492A (en) * 1997-05-28 2000-08-29 Jenner Biotherapies, Inc. Immunogenic compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy

Similar Documents

Publication Publication Date Title
TAN et al. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review
Wang et al. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor
He et al. Advances in aluminum hydroxide-based adjuvant research and its mechanism
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
Wang et al. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
JP2011500662A5 (enExample)
Zhao et al. O/W nanoemulsion as an adjuvant for an inactivated H3N2 influenza vaccine: based on particle properties and mode of carrying
JP2010500398A5 (enExample)
ATE555808T1 (de) Impfstoffzusammensetzung mit einem synthetischen adjuvans
JP2007327074A5 (enExample)
KR102823291B1 (ko) 종양-관련된 항원 에피토프의 미생물 서열 변이체
JP2014502156A5 (enExample)
Maciel et al. Immunomodulation and nitric oxide restoration by a probiotic and its activity in gut and peritoneal macrophages in diabetic rats
JP5591705B2 (ja) 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用
JP2006232799A (ja) ポリ−γ−グルタミン酸含有免疫補強剤組成物
RU2017101091A (ru) Композиции вакцин с двойным адъювантом, получение и применения
CN106075419B (zh) 一种杀鲑气单胞菌灭活疫苗及其应用
JP2018500878A5 (enExample)
Emerson et al. Extracellular vesicles elicit protective immune responses against Salmonella infection
JP2014511856A5 (enExample)
Zhu et al. Characterization and evaluation of an oral vaccine via nano-carrier for surface immunogenic protein (Sip) delivery against Streptococcus agalactiae infection
Yu et al. A nanoparticle-based anticaries vaccine enhances the persistent immune response to inhibit Streptococcus mutans and prevent caries
Singh et al. Glycan-based shaping of the microbiota during primate evolution
PH12013500036A1 (en) Vaccine compositions based on sticholysin encapsulated into liposomes